Search

Displaying results 1881 - 1890 of 7687 in total
  1. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be

  2. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

    Synonyms: (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate, 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  3. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    FDA-approved test. … approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an

  4. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids. … Recent research shows that sodium benzoate may be beneficial as an add-on therapy (1 gram/day) in schizophrenia. Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.

    Mixtures: Prosed/DS
  5. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

  6. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. … [L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.

  7. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed

  8. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

  9. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]

  10. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

    Products: DOXOLEM RU, DOXORUBICIN AU 2MG/ML 10MG